Matthew Autterson has dedicated over 25 years to the industry of financial services. He currently serves as Board Member, President, and Chief Executive Officer of CNS Bioscience, INC., a clinical drug research company with a primary focus concerning neuropathic pain.
Autterson holds deep ties within the Colorado business climate, where his skills in wealth management, wealth management consulting, and private wealth management have earned him a great deal of success. As a graduate of the University of Denver Tax Program, Autterson began his career at First Trust Corporation, a subsidiary of Fiserv.
Autterson worked his way through the world of financial trust companies until he became president of Resources Trust Company, largely regarded as the biggest state-charted financial institutions in the USA. Autterson later sold Resources Trust Company in 1989 to SunAmerica which was acquired in 1998 for $18 billion.
As a long standing member of the Board of Directors of Falci Adaptive Biosystems, a non-profit focused on helping those suffering from neuromotor disabilities, Autterson’s interest in helping humanity has gained him much respect in the business world of his hometown, Denver, Colorado.
Mr. Autterson also holds a rich history pursuing his interest in giving back to the community– he has served on the Board of the Denver Zoo and Denver Zoological Foundation. Most touchingly, he has also served as Chairman of the Board of Directors of Denver Hospice. Several times throughout its history, Mr. Autterson’s donations have been the primary driving force behind the zoo’s success. His ties to the financial industry have brought in significant donations time and time again. Animal lovers have Matthew Autterson to thank for his uncanny ability to mix finances with the lighter side of life.
Matthew Autterson remains an integral part of the Colorado business world with his current endeavors as Board Member, President, and Chief Executive Officer (CEO) of CNS Bioscience, Inc., founded in 2013. If Autterson’s history is any telling of his track record, we are sure to see big, innovative, and exciting happenings take place in the name of neuropathic pain developments in coming years with Autterson at their head.